42 results on '"Audet, Susette"'
Search Results
2. Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules
3. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults
4. Measles Humoral and Cell-Mediated Immunity in Children Aged 5—10 Years After Primary Measles Immunization Administered at 6 or 9 Months of Age
5. Immunogenicity, Immunologic Memory, and Safety Following Measles Revaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy
6. Increasing the Time of Exposure to Aerosol Measles Vaccine Elicits an Immune Response Equivalent to That Seen in 9-Month-Old Mexican Children Given the Same Dose Subcutaneously
7. Persistence of Vaccine-Induced Measles Antibody Beyond Age 12 Months: A Comparison of Response to One and Two Doses of Edmonston-Zagreb Measles Vaccine Among HIV-Infected and Uninfected Children in Malawi
8. Laboratory Characterization of Measles Virus Infection in Previously Vaccinated and Unvaccinated Individuals
9. Safety and Immunogenicity of Early Measles Vaccination in Children Born to HIV-Infected Mothers in the United States: Results of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 225
10. Antibody Induced by Immunization with the Jeryl Lynn Mumps Vaccine Strain Effectively Neutralizes a Heterologous Wild-Type Mumps Virus Associated with a Large Outbreak
11. Immunogenicity of Standard-Titer Measles Vaccine in HIV-1-Infected and Uninfected Zambian Children: An Observational Study
12. Measles-Virus-Neutralizing Antibodies in Intravenous Immunoglobulins
13. Humoral and Cell-Mediated Immune Responses to an Early 2-Dose Measles Vaccination Regimen in the United States
14. Induction of Cellular and Humoral Immunity after Aerosol or Subcutaneous Administration of Edmonston-Zagreb Measles Vaccine as a Primary Dose to 12-Month-Old Children
15. Immune Responses to Measles and Mumps Vaccination of Infants at 6, 9, and 12 Months
16. The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants
17. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination
18. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children
19. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII ® at 15 months of age and antibody levels at 27 months of age
20. Antiproliferative action of interferon-α requires components of T-cell-receptor signalling
21. Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment
22. Evaluation of an Early Two-Dose Measles Vaccination Schedule
23. Measles Maternal Antibodies With Low Avidity Do Not Interfere With the Establishment of Robust Quantity and Quality Antibody Responses After the Primary Dose of Measles, Mumps, and Rubella Vaccine Administered at 12-Months of Age
24. Development of a high-throughput assay to measure measles neutralizing antibodies
25. Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein
26. Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling
27. Measles Maternal Antibodies With Low Avidity Do Not Interfere With the Establishment of Robust Quantity and Quality Antibody Responses After the Primary Dose of Measles, Mumps, and Rubella Vaccine Administered at 12-Months of Age.
28. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults
29. Development of a Luciferase Immunoprecipitation System Assay To Detect IgG Antibodies against Human Respiratory Syncytial Virus Nucleoprotein
30. 1339Measles and Mumps Antibody Response in Young Adults after a Third Dose of Measles-Mumps-Rubella Vaccine
31. A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment
32. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants
33. ELISA underestimates measles antibody seroprevalence in US military recruits
34. Identification of Linear Heparin-Binding Peptides Derived from Human Respiratory Syncytial Virus Fusion Glycoprotein That Inhibit Infectivity
35. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII® at 15 months of age and antibody levels at 27 months of age
36. Cellular and humoral immune responses to measles in immune adults re-immunized with measles vaccine
37. The Fusion Glycoprotein of Human Respiratory Syncytial Virus Facilitates Virus Attachment and Infectivity via an Interaction with Cellular Heparan Sulfate
38. Divergence of Binding, Signaling, and Biological Responses to Recombinant Human Hybrid IFN
39. IL-12, IFN-γ, and T Cell Proliferation to Measles in Immunized Infants
40. Prolonged STAT1 Activation Related to the Growth Arrest of Malignant Lymphoma Cells by Interferon-α
41. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.
42. Follow-up of infants given measles vaccine at 6 months of age: antibody and CMI responses to MMRII® at 15 months of age and antibody levels at 27 months of age
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.